Back to News
Market Impact: 0.2
Insilico Unveils AI-Designed ISM9546 For Inflammatory Bowel Disease And Rheumatoid Arthritis
Source: Nasdaq
Artificial IntelligenceHealthcare & BiotechTechnology & InnovationProduct Launches
Insilico Medicine nominated ISM9546, an experimental drug candidate designed using generative AI to target autoimmune diseases, including inflammatory bowel disease. The article reports a drug-discovery milestone but gives no clinical results or development timeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Why is Samsung Electronics stock plunging today?
- SK Hynix plunges 8% amid Asia tech rout as Fed rate hike fears, AI funding worries mount
- Elon Musk says Trump is 'ultimately' responsible for any curbs on Ukraine's Starshield systems
- SK Hynix seeks U.S. chip equipment exports to China tied to new factory
- Dell stock plunges 11%, leading data center sell-off on concerns about 'enterprise AI timing'
- Why is Rocket Lab stock tumbling today?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- State of Public Markets, June 2026: Higher for Longer Meets the AI Supercycle
- AI Research Tools With Exact Source Citations